TMMC4: A Potential Drug Target and Biomarker for Ovarian Cancer

Target Name: TMTC4

NCBI ID: G84899

TMTC4

TMMC4: A Potential Drug Target and Biomarker for Ovarian Cancer

Ovarian cancer is a leading cause of cancer death in women, with over 21,000 new cases and 15,000 deaths in the United States alone in 2020. Despite advances in treatment, the survival rate for ovarian cancer has remained largely the same due to the lack of effective targeted therapies. The search for new treatments and biomarkers has led to the identification of potential drug targets, including TMMC4, a gene that has been identified as a potential drug target and biomarker for ovarian cancer.

TMMC4: The Gene and Its Function

TMMC4 is a gene that encodes a protein known as tubulin-associated protein 4. It is a member of the tubulin-associated protein family, which is a family of proteins that are involved in microtubule dynamics and stability. TMMC4 is expressed in various tissues, including the brain, pancreas, and gastrointestinal tract, but its expression is highest in ovarian cancer cells.

The Role of TMMC4 in Ovarian Cancer

Studies have shown that TMMC4 is involved in various aspects of ovarian cancer development, including the regulation of cell growth, apoptosis (programmed cell death), angiogenesis (the formation of new blood vessels), and the maintenance of stem cell self-renewal. In addition, TMMC4 has been shown to promote the development of ovarian cancer by increasing the sensitivity of cancer cells to chemotherapy and inhibiting the development of cancer cells in animal models.

TMMC4 as a Drug Target

The potential drug target for TMMC4 is based on its involvement in ovarian cancer development and its regulation by various signaling pathways. Drugs that target TMMC4 have the potential to inhibit its activity and reduce the growth and spread of ovarian cancer.

One approach to targeting TMMC4 is to use small molecules, such as inhibitors of the tubulin-associated protein 4 kinase, a protein that is involved in the regulation of TMMC4 activity. Small molecules have been shown to be effective in inhibiting the activity of tubulin-associated protein 4 kinase in various cell types, including cancer cells.

Another approach to targeting TMMC4 is to use antibodies that recognize and target the protein itself. This approach has been shown to be effective in inhibiting the activity of TMMC4 in ovarian cancer cells and mouse models.

TMMC4 as a Biomarker

The expression of TMMC4 has been shown to be elevated in various ovarian cancer samples, including primary ovarian cancer tumors, metastatic ovarian cancer, and recurrent ovarian cancer. This suggests that TMMC4 may be a useful biomarker for ovarian cancer diagnosis and monitoring.

In addition, some studies have shown that TMMC4 levels have decreased in ovarian cancer cells that were treated with chemotherapy, indicating that it may be a potential biomarker for ovarian cancer treatment.

Conclusion

TMMC4 is a gene that has been identified as a potential drug target and biomarker for ovarian cancer. Its involvement in various aspects of ovarian cancer development, including cell growth, apoptosis, angiogenesis, and stem cell self-renewal, makes it an attractive target for small molecules and antibodies. Further studies are needed to determine the effectiveness of targeting TMMC4 in ovarian cancer.

Protein Name: Transmembrane O-mannosyltransferase Targeting Cadherins 4

Functions: Transfers mannosyl residues to the hydroxyl group of serine or threonine residues. The 4 members of the TMTC family are O-mannosyl-transferases dedicated primarily to the cadherin superfamily, each member seems to have a distinct role in decorating the cadherin domains with O-linked mannose glycans at specific regions. Also acts as O-mannosyl-transferase on other proteins such as PDIA3

The "TMTC4 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about TMTC4 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets